Marc Banjak
Net worth: 35 000 $ as of 2026-07-30
Net worth: 35 000 $ as of 2026-07-30
Marc A. Banjak is currently Chief Legal Officer at iBio, Inc. since 2025.
Formerly, Mr. Banjak was General Counsel at Istari Oncology, Inc., General Counsel at Dova Pharmaceuticals, Inc. from 2017 to 2021, and a Member of The Colorado Bar Association.
Education includes undergraduate studies at Franklin & Marshall College and graduate studies at Sturm College of Law.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IBIO, INC. 0.07% | 2026-03-25 | 25,000 ( 0.07% ) | 35 000 $ | 2026-07-30 |
| Companies | Position | Start |
|---|---|---|
| IBIO, INC. | General Counsel | - |
| Companies | Position | End |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | General Counsel | 2021-03-31 |
The Colorado Bar Association | Corporate Officer/Principal | - |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Comptroller/Controller/Auditor | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Colorado Bar Association | |
iBio, Inc.
iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Sturm College of Law
Sturm College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Health Technology |
Select your edition
All financial news and data tailored to specific country editions